AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

ANAB Stock Forecast

AnaptysBio stock forecast is as follows: an average price target of $52.00 (represents a 175.42% upside from ANAB’s last price of $18.88) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

ANAB Price Target

The average price target for AnaptysBio (ANAB) is $52.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $30.00. This represents a potential 175.42% upside from ANAB's last price of $18.88.

ANAB Analyst Ratings

Buy

According to 10 Wall Street analysts, AnaptysBio's rating consensus is 'Buy'. The analyst rating breakdown for ANAB stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AnaptysBio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 06, 2024	Emily Bodnar	H.C. Wainwright	$52.00	$19.38	168.32%	175.42%
Nov 06, 2024	David Risinger	Leerink Partners	$45.00	$19.38	132.20%	138.35%
Oct 21, 2024	Yatin Suneja	Guggenheim	$90.00	$34.98	157.29%	376.69%
Oct 15, 2024	Yasmeen Rahimi	Piper Sandler	$80.00	$34.74	130.28%	323.73%
Oct 03, 2024	David Risinger	New Street	$35.00	$35.22	-0.62%	85.38%
Aug 15, 2024	Joon Lee	Truist Financial	$30.00	$34.65	-13.42%	58.90%
Apr 16, 2024	David Risinger	Leerink Partners	$47.00	$21.27	120.97%	148.94%
Nov 18, 2022	-	J.P. Morgan	$32.00	$29.16	9.74%	69.49%

Row per page

Go to

The latest AnaptysBio stock forecast, released on Nov 06, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $52.00, which represents a 168.32% increase from the stock price at the time of the forecast ($19.38), and a 175.42% increase from ANAB last price ($18.88).

AnaptysBio Price Target by Period

	1M	3M	12M
# Anlaysts	3	5	7
Avg Price Target	$62.33	$60.40	$54.14
Last Closing Price	$18.88	$18.88	$18.88
Upside/Downside	230.14%	219.92%	186.76%

In the current month, the average price target of AnaptysBio stock is $62.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 230.14% increase as opposed to AnaptysBio's last price of $18.88. This month's average price target is up 3.20% compared to last quarter, and up 15.13% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 21, 2024	Wedbush	Buy	Buy	Hold
Oct 21, 2024	Guggenheim	Buy	Buy	Hold
Oct 15, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 03, 2024	Leerink Partners	Outperform	Outperform	Hold
Sep 26, 2024	Wedbush	Buy	Buy	Hold
Aug 06, 2024	Wedbush	Buy	Buy	Hold
Aug 06, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 06, 2024	Wedbush	Outperform	Outperform	Hold
May 10, 2024	Wells Fargo	Buy	Buy	Hold

Row per page

Go to

AnaptysBio's last stock rating was published by H.C. Wainwright on Oct 30, 2024. The company gave ANAB a "Buy" rating, the same as its previous rate.

AnaptysBio Financial Forecast

AnaptysBio Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.32M	$3.46M	$1.37M	$6.81M	$1.29M	$1.22M	$970.00K	$1.01M	$20.89M	$30.03M	$11.25M	$60.00M	-
Avg Forecast	$30.41M	$30.02M	$30.02M	$30.02M	$30.02M	$30.02M	$30.02M	$30.02M	$12.30M	$13.29M	$11.17M	$10.95M	$10.10M	$8.21M	$22.76M	$4.00M	$3.79M	$2.29M	$2.68M	$2.90M	$5.78M	$13.43M	$5.30M	$5.05M	$976.00K	$6.65M	$28.88M	$9.39M	$80.00M	$2.00M
High Forecast	$62.12M	$61.32M	$61.32M	$61.32M	$61.32M	$61.32M	$61.32M	$61.32M	$25.12M	$27.15M	$22.82M	$20.69M	$22.47M	$16.76M	$22.76M	$4.00M	$4.04M	$2.31M	$5.48M	$5.92M	$11.82M	$13.43M	$5.30M	$5.05M	$976.00K	$6.65M	$28.88M	$9.39M	$80.00M	$2.00M
Low Forecast	$13.97M	$13.79M	$13.79M	$13.79M	$13.79M	$13.79M	$13.79M	$13.79M	$5.65M	$6.11M	$5.13M	$7.24M	$2.25M	$3.77M	$22.76M	$4.00M	$3.46M	$2.26M	$1.23M	$1.33M	$2.66M	$13.43M	$5.30M	$5.05M	$976.00K	$6.65M	$28.88M	$9.39M	$80.00M	$2.00M
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.45%	1.29%	0.47%	1.18%	0.10%	0.23%	0.19%	1.04%	3.14%	1.04%	1.20%	0.75%	-

AnaptysBio's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.79M, with a low forecast of $3.46M, and a high forecast of $4.04M. ANAB's average Quarter revenue forecast represents a 14.09% increase compared to the company's last Quarter revenue of $3.32M (Sep 23).

AnaptysBio EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-37.73M	$-40.14M	$-39.92M	$-22.14M	$-26.78M	$-26.11M	$-30.83M	$-33.60M	$-6.00M	$482.00K	$-18.04M	$33.79M	$-23.63M
Avg Forecast	$-25.18M	$-24.85M	$-24.85M	$-24.85M	$-24.85M	$-24.85M	$-24.85M	$-24.85M	$-10.18M	$-11.00M	$-9.25M	$-9.07M	$-8.37M	$-6.79M	$-18.84M	$-18.24M	$-3.13M	$-1.89M	$-2.22M	$-19.51M	$-4.79M	$-11.14M	$-4.40M	$-20.86M	$-810.12K	$-5.52M	$-23.97M	$-18.82M	$-66.40M	$-1.66M
High Forecast	$-11.57M	$-11.42M	$-11.42M	$-11.42M	$-11.42M	$-11.42M	$-11.42M	$-11.42M	$-4.68M	$-5.06M	$-4.25M	$-6.00M	$-1.86M	$-3.12M	$-18.84M	$-14.59M	$-2.87M	$-1.87M	$-1.02M	$-15.61M	$-2.20M	$-11.14M	$-4.40M	$-16.69M	$-810.12K	$-5.52M	$-23.97M	$-15.06M	$-66.40M	$-1.66M
Low Forecast	$-51.44M	$-50.77M	$-50.77M	$-50.77M	$-50.77M	$-50.77M	$-50.77M	$-50.77M	$-20.80M	$-22.48M	$-18.90M	$-17.13M	$-18.60M	$-13.88M	$-18.84M	$-21.89M	$-3.34M	$-1.92M	$-4.54M	$-23.41M	$-9.78M	$-11.14M	$-4.40M	$-25.04M	$-810.12K	$-5.52M	$-23.97M	$-22.59M	$-66.40M	$-1.66M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.91%	18.06%	2.05%	4.62%	2.40%	5.94%	1.48%	41.48%	1.09%	-0.02%	0.96%	-0.51%	14.23%

2 analysts predict ANAB's average Quarter EBITDA for Sep 21 to be $-5.52M, with a high of $-5.52M and a low of $-5.52M. This is -1245.91% lower than AnaptysBio's previous annual EBITDA (Jun 21) of $482.00K.

AnaptysBio Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-37.31M	$-39.84M	$-48.45M	$-26.41M	$-37.37M	$-37.31M	$-40.76M	$-31.09M	$-6.67M	$-429.00K	$-18.16M	$33.65M	$-23.77M
Avg Forecast	$-23.86M	$-21.01M	$-18.64M	$-17.96M	$-43.31M	$-40.15M	$-38.90M	$-37.72M	$-41.72M	$-44.64M	$-43.59M	$-54.62M	$-44.82M	$-47.58M	$-30.07M	$-21.45M	$-46.25M	$-51.34M	$-48.99M	$-22.94M	$35.76M	$-17.02M	$-26.86M	$-24.54M	$-27.08M	$-23.26M	$-2.81M	$-18.95M	$53.14M	$-19.74M
High Forecast	$-7.09M	$-6.25M	$-5.54M	$-5.34M	$-12.88M	$-11.94M	$-11.57M	$-11.22M	$-12.41M	$-13.27M	$-12.96M	$-19.53M	$-23.27M	$-14.15M	$-8.94M	$-17.16M	$-40.93M	$-15.27M	$-14.57M	$-18.35M	$42.91M	$-17.02M	$-26.86M	$-19.63M	$-27.08M	$-23.26M	$-2.81M	$-15.16M	$53.14M	$-19.74M
Low Forecast	$-56.21M	$-49.49M	$-43.92M	$-42.31M	$-102.03M	$-94.58M	$-91.63M	$-88.87M	$-98.29M	$-105.17M	$-102.68M	$-68.00M	$-52.86M	$-112.09M	$-70.84M	$-25.74M	$-55.29M	$-120.95M	$-115.40M	$-27.53M	$28.61M	$-17.02M	$-26.86M	$-29.44M	$-27.08M	$-23.26M	$-2.81M	$-22.74M	$53.14M	$-19.74M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	0.81%	2.11%	-0.74%	2.20%	1.39%	1.66%	1.15%	0.29%	0.15%	0.96%	0.63%	1.20%

AnaptysBio's average Quarter net income forecast for Mar 21 is $-18.95M, with a range of $-22.74M to $-15.16M. ANAB's average Quarter net income forecast represents a -156.33% decrease compared to the company's last Quarter net income of $33.65M (Dec 20).

AnaptysBio SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$10.17M	$10.68M	$10.82M	$9.41M	$8.86M	$8.17M	$10.20M	$5.39M	$5.43M	$5.25M	$5.42M	$5.09M	$4.79M
Avg Forecast	$52.37M	$51.69M	$51.69M	$51.69M	$51.69M	$51.69M	$51.69M	$51.69M	$21.18M	$22.89M	$19.24M	$18.86M	$17.40M	$14.13M	$39.19M	$6.89M	$6.52M	$3.94M	$4.62M	$4.99M	$5.41M	$23.12M	$9.12M	$8.70M	$1.68M	$11.46M	$49.74M	$5.66M	$137.76M	$3.44M
High Forecast	$106.98M	$105.60M	$105.60M	$105.60M	$105.60M	$105.60M	$105.60M	$105.60M	$43.26M	$46.75M	$39.30M	$35.63M	$38.69M	$28.87M	$39.19M	$6.89M	$6.96M	$3.99M	$9.44M	$10.19M	$6.49M	$23.12M	$9.12M	$8.70M	$1.68M	$11.46M	$49.74M	$6.79M	$137.76M	$3.44M
Low Forecast	$24.06M	$23.75M	$23.75M	$23.75M	$23.75M	$23.75M	$23.75M	$23.75M	$9.73M	$10.52M	$8.84M	$12.47M	$3.87M	$6.49M	$39.19M	$6.89M	$5.96M	$3.90M	$2.12M	$2.29M	$4.33M	$23.12M	$9.12M	$8.70M	$1.68M	$11.46M	$49.74M	$4.53M	$137.76M	$3.44M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.58%	2.31%	2.17%	1.74%	0.38%	0.90%	1.17%	3.21%	0.47%	0.11%	0.96%	0.04%	1.39%

AnaptysBio's average Quarter SG&A projection for Dec 23 is $6.52M, based on 4 Wall Street analysts, with a range of $5.96M to $6.96M. The forecast indicates a -35.92% fall compared to ANAB last annual SG&A of $10.17M (Sep 23).

AnaptysBio EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.41	$-1.50	$-1.73	$-0.93	$-1.32	$-1.32	$-1.47	$-1.13	$-0.24	$-0.02	$-0.66	$1.23	$-0.87
Avg Forecast	$-0.83	$-0.73	$-0.65	$-0.62	$-1.50	$-1.39	$-1.35	$-1.31	$-1.44	$-1.55	$-1.51	$-1.89	$-1.55	$-1.65	$-1.04	$-1.57	$-1.60	$-1.78	$-1.70	$-1.03	$-0.96	$-0.62	$-0.98	$-0.99	$-0.99	$-0.85	$-0.10	$-0.69	$1.94	$-0.72
High Forecast	$-0.25	$-0.22	$-0.19	$-0.18	$-0.45	$-0.41	$-0.40	$-0.39	$-0.43	$-0.46	$-0.45	$-0.68	$-0.81	$-0.49	$-0.31	$-0.47	$-1.42	$-0.53	$-0.50	$-0.31	$-0.28	$-0.62	$-0.98	$-0.99	$-0.99	$-0.85	$-0.10	$-0.69	$1.94	$-0.72
Low Forecast	$-1.95	$-1.71	$-1.52	$-1.46	$-3.53	$-3.27	$-3.17	$-3.08	$-3.40	$-3.64	$-3.55	$-2.35	$-1.83	$-3.88	$-2.45	$-3.69	$-1.91	$-4.19	$-3.99	$-2.43	$-2.25	$-0.62	$-0.98	$-0.99	$-0.99	$-0.85	$-0.10	$-0.69	$1.94	$-0.72
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.79%	0.88%	1.68%	0.97%	2.12%	1.34%	1.48%	1.14%	0.28%	0.19%	0.96%	0.63%	1.21%

According to 2 Wall Street analysts, AnaptysBio's projected average Quarter EPS for Mar 21 is $-0.69, with a low estimate of $-0.69 and a high estimate of $-0.69. This represents a -155.96% decrease compared to ANAB previous annual EPS of $1.23 (Dec 20).

AnaptysBio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CTMX	CytomX Therapeutics	$0.86	$5.73	566.28%	Buy
ANAB	AnaptysBio	$18.88	$52.00	175.42%	Buy
KURA	Kura Oncology	$16.04	$26.00	62.09%	Buy
CRNX	Crinetics Pharmaceuticals	$53.70	$70.14	30.61%	Buy
DCPH	Deciphera Pharmaceuticals	$25.59	$26.32	2.85%	Hold
RYTM	Rhythm Pharmaceuticals	$58.50	$55.20	-5.64%	Buy

ANAB Forecast FAQ

Is AnaptysBio a good buy?

Yes, according to 10 Wall Street analysts, AnaptysBio (ANAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of ANAB's total ratings.

What is ANAB's price target?

AnaptysBio (ANAB) average price target is $52 with a range of $30 to $90, implying a 175.42% from its last price of $18.88. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AnaptysBio stock go up soon?

According to Wall Street analysts' prediction for ANAB stock, the company can go up by 175.42% (from the last price of $18.88 to the average price target of $52), up by 376.69% based on the highest stock price target, and up by 58.90% based on the lowest stock price target.

Can AnaptysBio stock reach $30?

ANAB's average twelve months analyst stock price target of $52 supports the claim that AnaptysBio can reach $30 in the near future.

What is AnaptysBio's current price target trend?

3 Wall Street analysts forecast a $62.33 price target for AnaptysBio (ANAB) this month, up 230.14% from its last price of $18.88. Compared to the last 3 and 12 months, the average price target increased by 219.92% and increased by 186.76%, respectively.

What are AnaptysBio's analysts' financial forecasts?

AnaptysBio's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $120.07M (high $245.29M, low $55.17M), average EBITDA is $-99.418M (high $-45.682M, low $-203M), average net income is $-160M (high $-47.598M, low $-377M), average SG&A $206.76M (high $422.39M, low $95.01M), and average EPS is $-5.54 (high $-1.647, low $-13.052). ANAB's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $120.46M (high $246.09M, low $55.35M), average EBITDA is $-99.743M (high $-45.831M, low $-204M), average net income is $-81.472M (high $-24.226M, low $-192M), average SG&A $207.44M (high $423.77M, low $95.32M), and average EPS is $-2.82 (high $-0.838, low $-6.643).

Did the ANAB's actual financial results beat the analysts' financial forecasts?

Based on AnaptysBio's last annual report (Dec 2022), the company's revenue was $10.29M, which missed the average analysts forecast of $29.56M by -65.20%. Apple's EBITDA was $-108M, beating the average prediction of $-41.193M by 161.19%. The company's net income was $-129M, beating the average estimation of $-32.657M by 294.16%. Apple's SG&A was $36.64M, missing the average forecast of $46.35M by -20.95%. Lastly, the company's EPS was $-4.57, beating the average prediction of $-3.556 by 28.52%. In terms of the last quarterly report (Sep 2023), AnaptysBio's revenue was $3.32M, beating the average analysts' forecast of $2.29M by 44.98%. The company's EBITDA was $-37.732M, beating the average prediction of $-1.895M by 1891.22%. AnaptysBio's net income was $-37.308M, missing the average estimation of $-51.344M by -27.34%. The company's SG&A was $10.17M, beating the average forecast of $3.94M by 158.11%. Lastly, the company's EPS was $-1.41, missing the average prediction of $-1.777 by -20.65%